OSAKA - Japanese pharmaceutical firm Shionogi & Co. will provide up to 120 million doses of its COVID-19 vaccine under development annually or enough for 60 million people, doubling its supply plan as it found a lower dosage was still efficacious, according to the company.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
